Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accumulated Expenses (2016 - 2025)

Ani Pharmaceuticals' Accumulated Expenses history spans 16 years, with the latest figure at $16.8 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 25.74% year-over-year to $16.8 million; the TTM value through Dec 2025 reached $16.8 million, down 25.74%, while the annual FY2025 figure was $16.8 million, 25.74% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $16.8 million at Ani Pharmaceuticals, up from $14.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $32.9 million in Q2 2025 and bottomed at $4.9 million in Q3 2021.
  • The 5-year median for Accumulated Expenses is $10.1 million (2022), against an average of $12.3 million.
  • The largest annual shift saw Accumulated Expenses tumbled 50.94% in 2022 before it skyrocketed 376.12% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $8.5 million in 2021, then rose by 21.0% to $10.3 million in 2022, then soared by 130.66% to $23.8 million in 2023, then fell by 4.88% to $22.6 million in 2024, then decreased by 25.74% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Accumulated Expenses are $16.8 million (Q4 2025), $14.0 million (Q3 2025), and $32.9 million (Q2 2025).